Cargando…

Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy

INTRODUCTION: Post-marketing data have demonstrated the potential for weight gain with integrase inhibitors (INSTI) use in antiretroviral (ART) therapy. METHODS: A medical chart review evaluated virologically suppressed adult prisoners living with HIV and on a non-INSTI regimen before switching or a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldberg, Rachel N., Kania, Alexandra T., Michienzi, Sarah M., Patel, Mahesh, Badowski, Melissa E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Emerging Issues in Antiretroviral Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917853/ https://www.ncbi.nlm.nih.gov/pubmed/33626965 http://dx.doi.org/10.1177/2325958221996860

Ejemplares similares

Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients
por: Beer, Linda, et al.
Publicado: (2015)

Association of HIV/AIDS Clinician Warm Line Utilization with Diagnosis and Management of Antiretroviral Treatment Failure in Mozambique: A Retrospective Analysis of Program Data
por: Ruano Camps, Maria, et al.
Publicado: (2017)

941. Incarcerated patients living with HIV: Atherosclerotic cardiovascular disease risk and management
por: Michienzi, Sarah M, et al.
Publicado: (2020)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

1049. Weight Gain in Persons Living with HIV (PLWH) Treated with Bictegravir Compared to Other Integrase Strand Transfer Inhibitors
por: Fang, Michelle, et al.
Publicado: (2020)

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
por: Donga, Prina, et al.
Publicado: (2022)

939. Immunity to Hepatitis A and/or Hepatitis B Viruses Among Inmates Living with HIV
por: Poondi, Nivedha, et al.
Publicado: (2020)

No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain
por: Verburgh, Myrthe L., et al.
Publicado: (2023)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor
por: Verburgh, Myrthe L, et al.
Publicado: (2022)

2060. Evaluation of the real world incidence of integrase inhibitor resistance since adoption as guideline preferred therapy
por: Januszka, Jenna, et al.
Publicado: (2022)

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
por: Saber, Saghar, et al.
Publicado: (2019)

Incarcerated Epigastric Hernia
por: Das, Snehasis, et al.
Publicado: (2022)

Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort
por: Koay, Wei Li A, et al.
Publicado: (2021)

Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV
por: Michienzi, Sarah M., et al.
Publicado: (2021)

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
por: Amico, K. Rivet, et al.
Publicado: (2014)

Biomedical Prevention: State of the Science
por: McCormack, Sheena M., et al.
Publicado: (2014)

Leveraging HIV Treatment to End AIDS, Stop New HIV Infections, and Avoid the Cost of Inaction
por: Sidibé, Michel, et al.
Publicado: (2014)

Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy
por: Chastain, Daniel, et al.
Publicado: (2019)

1043. The impact of integrase strand transfer inhibitors (InSTIs) on weight gain among adults with HIV in clinical care
por: Thatipelli, Sneha, et al.
Publicado: (2020)

COVID-19 Outcomes and Risk Factors Among People Living with HIV
por: Spinelli, Matthew A., et al.
Publicado: (2022)

Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection
por: Wu, Kuan-Sheng, et al.
Publicado: (2020)

Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
por: Kim, Jin, et al.
Publicado: (2022)

946. Risk factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain
por: Asundi, Archana, et al.
Publicado: (2020)

1313. Complementary Effects of Medical Follow-up and Virologic Suppression for Reincarcerated Inmates Living with HIV
por: Badowski, Melissa E, et al.
Publicado: (2019)

Hematemesis Secondary to Complex Incarcerated Pantaloon Hernia
por: Huang, Derrick, et al.
Publicado: (2021)

1987. "Association Between Integrase Inhibitor Plasma Concentrations and Body Weight Gain in Women Living with HIV"
por: Lahiri, Cecile D, et al.
Publicado: (2023)

333. Weight Gain Among HIV-Infected Patients in Southern India on Treatment with Integrase Strand Transfer Inhibitor-based Antiretroviral Therapy
por: Khan, Rifa, et al.
Publicado: (2019)

An Unusual Presentation of Spigelian Hernia Incarceration after Colonoscopy
por: Pronesti, Vincent M, et al.
Publicado: (2018)

TNFα: role in post-dieting weight gain?
Publicado: (2012)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Bunnell, Kristen L., et al.
Publicado: (2018)

952. Weight-Gain in Treatment Naive Newly Diagnosed HIV-Infected Persons After Initiation on Integrase Strand Inhibitor Based Treatment Regimens
por: Szep, Zsofia, et al.
Publicado: (2020)

Can vitamins and/or supplements provide hope against coronavirus?
por: Michienzi, Sarah M, et al.
Publicado: (2020)

332. Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
por: Zimmerman, Matty, et al.
Publicado: (2019)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGE(h)IV cohort participants
por: Verboeket, Sebastiaan O., et al.
Publicado: (2021)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
por: Wood, Brian R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_upk6kvc18d2pr6mnouj7v2l667